AbCellera Biologics Inc.
ABCL
Rangering i aksjer
#4244
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Aksjekurs
$11.61
Markedsverdi
$3.76B
Endring (1 dag)
-2.68%
Endring (1 år)
98.12%
Land
CA
Handel AbCellera Biologics Inc. (ABCL)
Kategori
Healthcare
P/B-forhold for AbCellera Biologics Inc. (ABCL)
P/B-forhold per October 2026 TTM: 4.22
Ifølge AbCellera Biologics Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 4.22. Ved slutten av 2023 hadde selskapet et P/B-forhold på 1.43.
P/B-historikk for AbCellera Biologics Inc. fra 2018 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 4.22 | 414.44% |
| 2024 | 0.82 | -43.01% |
| 2023 | 1.43 | -38.80% |
| 2022 | 2.34 | -39.10% |
| 2021 | 3.84 | -70.56% |
| 2020 | 13.06 | -98.53% |
| 2019 | 885.28 | 15.51% |
| 2018 | 766.43 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | 48.18% |
US
|
|
| 13.2547 | 214.21% |
US
|
|
| 4.208 | -0.25% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 46.56% |
NL
|
